Copyright
©2009 The WJG Press and Baishideng. All rights reserved.
World J Gastroenterol. Aug 14, 2009; 15(30): 3814-3816
Published online Aug 14, 2009. doi: 10.3748/wjg.15.3814
Published online Aug 14, 2009. doi: 10.3748/wjg.15.3814
Adalimumab in ulcerative colitis: Two cases of mucosal healing and clinical response at two years
Manuel Barreiro-de Acosta, Aurelio Lorenzo, Juan Enrique Dominguez-Muñoz, Department of Gastroenterology, University Hospital of Santiago de Compostela, C/Choupana, s/n, E-15706-Santiago de Compostela, Spain
Author contributions: Barreiro-de Acosta M and Dominguez-Muñoz JE designed the research; Barreiro-de Acosta M and Lorenzo A performed the research; Barreiro-de Acosta M wrote the paper.
Correspondence to: Manuel Barreiro-de Acosta, MD, PhD, Department of Gastroenterology, University Hospital of Santiago de Compostela, C/Choupana, s/n, E-15706-Santiago de Compostela, Spain. mbarreirodeacosta@hotmail.es
Telephone: +34-696-990188
Fax: +34-981-955100
Received: May 14, 2009
Revised: July 4, 2009
Accepted: July 11, 2009
Published online: August 14, 2009
Revised: July 4, 2009
Accepted: July 11, 2009
Published online: August 14, 2009
Abstract
Infliximab (IFX) is currently the only biologic therapy used in the treatment of moderate-to-severe ulcerative colitis (UC). In the years to come, more biologic therapies will have a role in the management of moderate-to-severe UC. We report on two patients with steroid-dependent UC who, due to adverse reactions to IFX, have been under therapy with adalimumab for two years. Both patients received concomitant immunosuppressive treatment. Long term clinical remission and mucosal healing are described.
Keywords: Adalimumab; Ulcerative colitis; Mucosal healing; Maintenance treatment